Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy

Cytotherapy

Volumn 18, Issue 1, 2016, Pages 91-98

  Qiu, Ying ^a   Yun, Mark M ^b   Dong, Xuebin ^c   Xu, Mingbao ^d   Zhao, Ruidong ^a   Han, Xia ^a   Zhou, Erxia ^a   Yun, Feiyu ^a   Su, Wuyun ^a   Liu, Caixia ^a   Zhao, Haiyan ^a   Tong, Xin ^e   Gao, Jin ^f   Ouyang, Xiaohui ^a   Yun, Sheng ^a  

^a Affiliated Hospital of Inner Mongolia Medical University   (China)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^e LANZHOU UNIVERSITY   (China)

^f Beijing Jing Meng Stem Cell Technology Co   (China)

Author keywords

Cytokine induced killer; Dendritic cell; Epitope; Immunotherapy; Refractory lymphoma; 1,3 galactosyl epitope

Indexed keywords

CANCER VACCINE; EPITOPE; GALACTOSE; GAMMA INTERFERON; TUMOR ANTIGEN;

ADULT; ADVERSE EFFECTS; AGED; ANIMAL; BOVINE; CELL MEMBRANE; CLINICAL TRIAL; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; LYMPHOMA, B-CELL; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROCEDURES; SECRETION (PROCESS); TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CATTLE; CELL MEMBRANE; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES; FEMALE; FLOW CYTOMETRY; GALACTOSE; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOCYTE SUBSETS; LYMPHOCYTES; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84955408256     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.09.012     Document Type: Article

References (35)

1. Li S.X., Zhu H.L., Guo B., Lu X.C., Fan H., Lin J., et al. Curative efficiency of rituximab combined with autologous cytokine induced killer cells on aged patient with orbital diffuse large B cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012, 20:1117-1121.
2. Yang B., Lu X.C., Yu R.L., Chi X.H., Liu Y., Wang Y., et al. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematol Oncol 2012, 30:115-122.
3. Lu X.C., Yang B., Yu R.L., Chi X.H., Tuo S., Tuo C.W., et al. Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma. Cell Biochem Biophys 2012, 62:257-265.
4. Seillet C., Belz G.T. Terminal differentiation of dendritic cells. Adv Immunol 2013, 120:185-210.
5. Hira S.K., Verma D., Manna P.P. Tumor antigen-/cytokine-pulsed dendritic cells in therapy against lymphoma. Methods Mol Biol 2014, 1139:45-56.
6. Aleixo A.A., Michelin M.A., Murta E.F. Immunotherapy with dendritic cells as a cancer treatment: perspectives and therapeutic potential. Recent Pat Endocr Metab Immune Drug Discov 2013, 7:226-232.
7. Ko E.C., Wang X., Ferrone S. Immunotherapy of malignant diseases: challenges and strategies. Int Arch Allergy Immunol 2003, 132:294-309.
8. Gerdemann U., Katari U., Christin A.S., Cruz C.R., Tripic T., Rousseau A., et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther 2011, 19:2258-2268.
9. Escors D. Tumor immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci 2014, 2014. 734515.
10. Galili U., LaTemple D.C. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997, 18:281-285.
11. Wang X.Y., Yi H., Yu X., Zuo D., Subjeck J.R. Enhancing antigen cross-presentation and T-cell priming by complexing protein antigen to recombinant large heat-shock protein. Methods Mol Biol 2011, 787:277-287.
12. Galili U. Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol Immunother 2004, 53:935-945.
13. LaTemple D.C., Henion T.R., Anaraki F., Galili U. Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 1996, 56:3069-3074.
14. LaTemple D.C., Galili U. Enhancement of autologous tumor vaccine immunogenicity by anti-Gal. Subcell Biochem 1999, 32:361-379.
15. Good A.H., Cooper D.K., Malcolm A.J., Ippolito R.M., Koren E., Neethling F.A., et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992, 24:559-562.
16. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993, 14:480-482.
17. Poirier N., Blancho G. Recombinant human C1-inhibitor inhibits cytotoxicity induced by allo- and xenoantibodies. Transplant Proc 2008, 40:581-583.
18. Buonomano R., Tinguely C., Rieben R., Mohacsi P.J., Nydegger U.E. Quantitation and characterization of anti alpha-1-3Gal antibodies in sera of 200 healthy persons. Xenotransplantation 1999, 6:173-180.
19. Hamanová M., Zdražilová Dubská L., Valík D., Lokaj J. Natural antibodies against α(1,3) galactosyl epitope in the serum of cancer patients. Epidemiol Mikrobiol Imunol 2014, 63:130-133.
20. Galili U., Chen Z.C., Manches O., Plumas J., Preisler H. Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes. J Hematother Stem Cell Res 2001, 10:501-511.
21. Manches O., Plumas J., Lui G., Chaperot L., Molens J.P., Sotto J.J., et al. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells. Haematologica 2005, 90:625-634.
22. Iwata-Kajihara T., Sumimoto H., Kawamura N., Ueda R., Takahashi T., Mizuguchi H., et al. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol 2011, 187:27-36.
23. Vasaturo A., Di Blasio S., Peeters D.G., de Koning C.C., de Vries J.M., Figdor C.G., et al. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for dc vaccination: a game of stop and go. Front Immunol 2013, 4:417.
24. Qiu Y., Yun M.M., Xu M.B., Wang Y.Z., Yun S. Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study. Int J Clin Oncol 2013, 18:657-665.
25. Qiu Y., Xu M.B., Yun M.M., Wang Y.Z., Zhang R.M., Meng X.K., et al. Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World J Gastroenterol 2011, 17:5260-5266.
26. Cheson B.D. Rethinking clinical response and outcome assessment in a biologic age. Curr Oncol Rep 2015, 17:27.
27. Miao L., Run-Ming J., Yi J. T-bet mediated anti-neoplastic effects of dendritic cell-cytokine induced killer cells in vitro. Iran J Pediatr 2012, 22:43-51.
28. Galili U., Rachmilewitz E.A., Peleg A., Flechner I. A unique natural human IgG antibody with anti α-galactosyl specificity. J Exp Med 1984, 160:1519-1531.
29. Wang D., Zhang B., Gao H., Ding G., Wu Q., Zhang J., et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer 2014, 14:251.
30. Yang L., Ren B., Li H., Yu J., Cao S., Hao X., et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 2013, 62:65-73.
31. Sun Y., Chen J., Cai P., Hu Y.H., Zhong G.C., Feng H.Z., et al. Therapy of relapsed or refractory non-Hodgkin's lymphoma by antigen specific dendritic cells-activated lymphocytes. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18:219-223.
32. Schmeel F.C., Schmeel L.C., Gast S.M., Schmidt-Wolf I.G. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci 2014, 15:14632-14648.
33. + cells in cytokine-induced killer cells. Zhonghua Yi Xue Za Zhi 2005, 85:3134-3138.
34. + cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother 2004, 53:1018-1026.
35. Hanke N., Alizadeh D., Katsanis E., Larmonier N. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol 2013, 33(1):1-21.